Evidence map›Paper›PMID 39379324›Full record

ArticlemAbs

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms.

Marianne Bachmann Salvy, Luca Santuari, Emanuel Schmid-Siegert, Nikolaos Lykoskoufis, Ioannis Xenarios, Bulak Arpat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. mAbs · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marianne Bachmann SalvyNGS-AI Division, JSR Life Sciences, Epalinges, Switzerland.ORCID 0009-0006-1528-8168
Luca SantuariNGS-AI Division, JSR Life Sciences, Epalinges, Switzerland.ORCID 0000-0001-8784-2507
Emanuel Schmid-SiegertNGS-AI Division, JSR Life Sciences, Epalinges, Switzerland.ORCID 0000-0003-1339-5120
Nikolaos LykoskoufisNGS-AI Division, JSR Life Sciences, Epalinges, Switzerland.ORCID 0000-0001-6751-7010
Ioannis XenariosNGS-AI Division, JSR Life Sciences, Epalinges, Switzerland.ORCID 0000-0002-3413-6841
Bulak ArpatNGS-AI Division, JSR Life Sciences, Epalinges, Switzerland.ORCID 0000-0002-7749-3793

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies have emerged as the leading class of biotherapeutics, yet traditional screening methods face significant time and resource challenges in identifying lead candidates. Integrating high-throughput sequencing with computational approaches marks a pivotal advancement in antibody discovery, expanding the antibody space to explore. In this context, a major breakthrough has been the full-length sequencing of single-chain variable fragments (scFvs) used in

Indexed as

High-Throughput Nucleotide SequencingSingle-Chain AntibodiesGene LibraryHumansImmunoglobulin Heavy ChainsPeptide LibrarySoftwareV(D)J RecombinationImmunoglobulin Heavy ChainsPeptide LibrarySingle-Chain AntibodiesAntibody discoverylong-read sequencingPacBiophage displayscFvs

Identifiers

PMID39379324
PMCPMC11469439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.